{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-016698","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2022-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.318373+00:00","generated_at":"2026-06-25T03:16:02.823098+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Arcutis Biotherapeutics reports positive Phase 3 STRATUM results for roflumilast foam in seborrheic dermatitis","bullets":["80.1% of patients on roflumilast foam achieved IGA success at week 8 vs 59.2% vehicle (p<0.0001)","50.7% achieved an IGA score of clear at week 8 compared to 28.2% with vehicle (p<0.0001)","Treatment was well-tolerated; discontinuation due to adverse events was 0.7% for roflumilast vs 2.0% for vehicle","NDA submission to FDA for roflumilast foam in seborrheic dermatitis anticipated in first half of 2023"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-016698","json":"https://secwatch.observer/filing/0001628280-22-016698.json","markdown":"https://secwatch.observer/filing/0001628280-22-016698.md","text":"https://secwatch.observer/filing/0001628280-22-016698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000162828022016698/0001628280-22-016698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000162828022016698/arqt-20220606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:16:02.823098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}